Do you want to read an article? Please log in or register.
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study
Leukemia
Indications
Related content
Leukemia
Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis
Leuk Lymphoma
Huang YH, Liu FT, Wan CL, Wang ZJ, Liu YQ, Cao HY, Huang SM, Tan KW, Ge SS, Wang M, Liu MJ, Wang ZH, Lyu XY, Dai HP, Li Z, Xue SL
doi: 10.1080/10428194.2025.2566317
Myeloproliferative Neoplasms (MPNs)
Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study
Leuk Lymphoma
Ciervo J, Perissinotti AJ, DiPippo AJ, Marx K, Benitez LL, Rausch C, Buhlinger K, Muluneh B, Hirata H, Baron J, Uchida E, Soule A, Griffin SP, Lee BJ, Lo M, Doan T, Martino J, Saunders I, Marini BL
doi: 10.1080/10428194.2026.2711164
Lung, Respiratory and Thoracic Cancer
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study
Ann Oncol
Zheng MM, Xia Y, Pan K, Sun F, Tan AC, Dong XR, Tu HY, Tang LB, Li YS, Yin K, Borgeaud M, Singhal S, Zhu E, Zhang J, Nilsson M, Wu J, Gibbons DL, Wakelee H, Neal JW, Lee J, Vaporciyan AA, Ringsurongkawong W, Tran HT, Zhang RZ, Zhang T, Zhou Q, Zhong WZ, Li W, Zhang YC, Riess JW, Addeo A, Heymach JV, Myall N, Tan D, Wu YL, Le X
doi: 10.1016/j.annonc.2025.09.140
Non-Malignant Blood Disorders
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
Am J Hematol
Fathima S, Wong MM, Gonzalez-Lugo J, Geyer SM, Alsugair A, Sirenko M, Langer KJ, Lasho TL, Finke C, Choi J, Abdul-Hay M, Ho G, Litzow MR, Matin A, Durani U, Hefazi M, Hogan WJ, Shah MV, Al-Kali A, Begna KH, Gangat N, Saliba AN, Go RS, Kewan T, Bartoo G, Kutzke J, McCullough K, Warrington KJ, Sullivan M, Reichard KK, Olteanu H, Murthy H, Badar T, Kusne Y, Palmer J, Chhabra S, Punwani N, Riwes M, McGuirk JP, Krakow EF, Langston A, Kourelis T, Dingli D, Foran J, Koster MJ, Patnaik MM, Beck DB, Alkhateeb HB, Mangaonkar AA
doi: 10.1002/ajh.70401
Gastrointestinal Cancer
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
Lancet Oncol
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A, CARES-310 Study Group
doi: 10.1016/S1470-2045(25)00543-1
Genitourinary Cancer
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study
Lancet Oncol
Karpinski MJ, Civan C, Rauscher I, Güven O, Eiber M, Hoberück S, Miederer M, Bundschuh RA, Hölscher T, Calais J, Theus L, Nguyen AT, Scholtissek H, Lapa C, Di Giorgio A, Farolfi A, Ufton D, Drzezga A, Kunikowska J, Pełka K, Evangelista L, Bauman G, Alçın G, Beintner-Skawran S, Rohani MFM, Miksch J, Hüsing A, Kesch C, Herrmann K, Stuschke M, Umutlu L, Gafita A, Hofman MS, Hope TA, Goffin K, Kind F, Pizzuto DA, Soeterik TFW, Kömek H, Emmett L, Vondrak A, Pinter T, Lanfranchi F, Bauckneht M, Unterrainer LM, Holzgreve A, Bjartell A, Trägårdh E, Rasul S, Miszczyk M, Bögemann M, Rodriguez SantAnna Jauregui N, Schäfers M, Rahbar K, Hadaschik BA, Fendler WP, PROMISE Registry Group
doi: 10.1016/S1470-2045(26)00016-1
Genitourinary Cancer
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study
Lancet Oncol
Soeterik TFW, Miszczyk M, Peters M, Bilski M, Francolini G, Garlatti P, Nicosia L, Alongi F, Mezeckis M, Kociolek J, Greco C, Techmański T, Huele EH, Teunissen FR, Westhoff PG, Vis W, Haverkort MAD, van der Voort van Zyp JRN, Intven MPW, van der Velden JM, Shariat SF, Eppinga WSC
doi: 10.1016/S1470-2045(25)00717-X
Central Nervous System Tumors
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group
Lancet Oncol
Karschnia P, Young JS, Wijnenga MMJ, Sciortino T, Teske N, Corell A, Wagner A, Youssef G, Park YW, Häni L, Jünger ST, Dono A, Ehret F, Mireles EEM, Neidert N, Bruno F, Tuchek CA, van der Vaart T, Rossi M, Nibali MC, Gay L, Gramelt A, Tandon N, Ahn SS, Chang JH, Weller M, Vincent AJPE, Goldbrunner R, Cahill DP, Huang RY, Raabe A, Meyer B, Beck J, Molinaro AM, Chang SM, Vogelbaum MA, Rudà R, Vik-Mo EO, Dietrich J, Esquenazi Y, Grau SJ, Wen PY, Jakola AS, Schnell O, Bello L, van den Bent MJ, Hervey-Jumper S, Berger MS, Tonn JC
doi: 10.1016/S1470-2045(25)00534-0
Skin Cancer
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients
Eur J Cancer
Ugurel S, Abu Rached N, Gambichler T, Mengoni M, Tüting T, Hassel JC, Reschke R, Lodde GC, Placke JM, Schadendorf D, Reinhardt L, Kreuter A, Gschnell M, Utikal J, Erdmann M, Dücker P, Helbig D, Franklin C, Gebhardt C, Poch G, Kähler KC, Weichenthal M, Gutzmer R, Heinzerling L, Weishaupt C, Mohr P, Thoms KM, Lang B, Schilling B, Haferkamp S, Sachse M, Welzel J, Jochims F, Raap U, Schley G, Terheyden P, Dippel E, Pöttgen C, Becker JC, Tasdogan A, Amaral T, Nanz L, Leiter U
doi: 10.1016/j.ejca.2025.115750